FDA Clears Riverain’s Chest X-ray Software

Article

Riverain Technologies has received FDA 510(k) clearance for software aimed at improving clarity of conventional chest X-rays.

Riverain Technologies has received FDA 510(k) clearance for software aimed at improving clarity of conventional chest X-rays, the company announced.

ClearRead + Confirm also allows radiologists to confirm the proper placement of tubes, lines, and wires, the company said. Portable chest X-ray machines, typically used to confirm line and tube placement, doesn’t have high quality images, and radiologists spend time adjusting the machines to make the edges stand out.

This software increases the readability of the chest X-ray by selectively increasing contrast and suppressing the clavicles and ribs in the image, removing items that could obscure visibility of the lines and tubes.

A Georgetown University reader study assessed the time it took radiologists to locate PICC lines, nasogastric tubes, and wires that conduct or measure electrical impulses. Ten radiologists reviewed 334 X-rays with and without the software, and the software reduced the reading time by 19 percent, according to the company.

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.